大湾生物

Our CMC platform is founded in 2002, and with over 30 million RMB investment on R&D equipment, and with over 300 million RMB for overall expenditure of R&D.

We have an excellent and independent technology platform for drug development and scaling up, and have successful experience in drug development; and some of projects are classified as “National New Drug Class 1”.

Our Platform has been recognized as “Company for Nurturing Patent”, “Pilot Company for Patent”, “and National High-tech Company ”,“ Innovative R&D institute in Dongguan ”,“ Great ten foreign R&D Center in Guangdong ”,“ Genetic Engineering and Drug Engineering Technology Research Center in Guangdong ”.

From 2016, we has been in charge of several government projects, and acquire several provincial and national project funding, including “Key Area Breakthrough Project in Guangdong and Hong Kong”, “National Key New Drug Development”, with more than 20 million RMB.

The Platform provides more than 3100 square meters for R&D, and is with whole set of cutting-edge biologics development equipment, which are mainly by the well-known international brand, like Sartorius, Bio-Rad, GE Healthcare, Waters.

Our workshop for pilot batch is designed following the GMP requirement. Our platform is built with a technical team of more than 40 people including Masters and Ph.D. Our team is capable for target discovery, sequence screening, plasmid development, cell line development, culture process development, sample purification, preparation research, product examination, etc., which includes all process from project screening to clinical sample production.